Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3555-3563

  Wu, Jinhui ^a   Song, Chenchen ^a   Jiang, Chenxiao ^a   Shen, Xin ^a   Qiao, Qian ^a   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antitumor therapy; Aptamer AS1411; Nanoparticle; Nucleolin targeting; Paclitaxel

Indexed keywords

APTAMER; AS1411; DRUG CARRIER; ENDOSTATIN; HUMAN SERUM ALBUMIN; NANOPARTICLE; NUCLEOLIN; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; ENDOSTATINS; HUMANS; MCF-7 CELLS; MICE; NANOPARTICLES; PACLITAXEL; PHOSPHOPROTEINS; RNA-BINDING PROTEINS;

EID: 84888321871     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300686g     Document Type: Article

References (34)

1. Gianni, L.; Kearns, C. M.; Giani, A.; Capri, G.; Vigano, L.; Lacatelli, A.; Bonadonna, G.; Egorin, M. J. Nonlinear Pharmacokinetics and Metabolism of Paclitaxel and Its Pharmacokinetic/Pharmacodynamic Relationships in Humans. J. Clin. Oncol. 1995, 13, 180-190.
2. Millward, M. J.; Webster, L. K.; Rischin, D.; Stokes, K. H.; Toner, G. C.; Bishop, J. F.; Olver, I. N.; Linahan, B. M.; Linsenmeyer, M. E.; Woodcock, D. M. Phase I Trial of Cremophor El with Bolus Doxorubicin. Clin. Cancer Res. 1998, 4, 2321-2329.
3. Singh, S.; Dash, A. K. Paclitaxel in Cancer Treatment: Perspectives and Prospects of Its Delivery Challenges. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26, 333-372.
4. Damascelli, B.; Cantu, G.; Mattavelli, F.; Tamplenizza, P.; Bidoli, P.; Leo, E.; Dosio, F.; Cerrotta, A. M.; Di Tolla, G.; Frigerio, L. F.; et al. Intraarterial Chemotherapy with Polyoxyethylated Castor Oil Free Paclitaxel, Incorporated in Albumin Nanoparticles (Abi-007): Phase II Study of Patients with Squamous Cell Carcinoma of the Head and Neck and Anal Canal: Preliminary Evidence of Clinical Activity. Cancer 2001, 92, 2592-2602.
5. Evora, C.; Soriano, I.; Rogers, R. A.; Shakesheff, K. N.; Hanes, J.; Langer, R. Relating the Phagocytosis of Microparticles by Alveolar Macrophages to Surface Chemistry: The Effect of 1, 2-Dipalmitoylphosphatidylcholine. J. Controlled Release 1998, 51, 143-152.
6. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-Based Nanoparticles as Potential Controlled Release Drug Delivery Systems. J. Controlled Release 2012, 157, 168-182.
7. Hawkins, M. J.; Soon-Shiong, P.; Desai, N. Protein Nanoparticles as Drug Carriers in Clinical Medicine. Adv. Drug Delivery Rev. 2008, 60, 876-885.
8. Wu, L.; Wu, J.; Zhou, Y.; Tang, X.; Du, Y.; Hu, Y. Enhanced Antitumor Efficacy of Cisplatin by Tirapazamine-Transferrin Conjugate. Int. J. Pharm. 2012, 431, 190-196.
9. Bates, P. J.; Laber, D. A.; Miller, D. M.; Thomas, S. D.; Trent, J. O. Discovery and Development of the G-Rich Oligonucleotide As1411 as a Novel Treatment for Cancer. Exp. Mol. Pathol. 2009, 86, 151-164.
10. Bunka, D. H. J.; Platonova, O.; Stockley, P. G. Development of Aptamer Therapeutics. Curr. Opin. Pharmacol. 2010, 10, 557-562.
11. Bates, P. J.; Kahlon, J. B.; Thomas, S. D.; Trent, J. O.; Miller, D. M. Antiproliferative Activity of G-Rich Oligonucleotides Correlates with Protein Binding. J. Biol. Chem. 1999, 274, 26369-26377.
12. Dapic, V.; Bates, P. J.; Trent, J. O.; Rodger, A.; Thomas, S. D.; Miller, D. M. Antiproliferative Activity of G-Quartet-Forming Oligonucleotides with Backbone and Sugar Modifications. Biochemistry 2002, 41, 3676-3685.
13. Xu, X.; Hamhouyia, F.; Thomas, S. D.; Burke, T. J.; Girvan, A. C.; McGregor, W. G.; Trent, J. O.; Miller, D. M.; Bates, P. J. Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by GRich Oligonucleotides. J. Biol. Chem. 2001, 276, 43221-43230.
14. Ireson, C. R.; Kelland, L. R. Discovery and Development of Anticancer Aptamers. Mol Cancer Ther. 2006, 5, 2957-2962.
15. Srivastava, M.; Pollard, H. B. Molecular Dissection of Nucleolin's Role in Growth and Cell Proliferation: New Insights. FASEB J. 1999, 13, 1911-1922.
16. Hovanessian, A. G.; Puvion-Dutilleul, F.; Nisole, S.; Svab, J.; Perret, E.; Deng, J. S.; Krust, B. The Cell-Surface-Expressed Nucleolin Is Associated with the Actin Cytoskeleton. Exp. Cell Res. 2000, 261, 312-328.
17. Cao, Z.; Tong, R.; Mishra, A.; Xu, W.; Wong, G. C.; Cheng, J.; Lu, Y. Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes. Angew. Chem., Int. Ed. Engl. 2009, 48, 6494-6498.
18. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-Functionalized Peg-Plga Nanoparticles for Enhanced Anti-Glioma Drug Delivery. Biomaterials 2011, 32, 8010-8020.
19. Barbas, A. S.; Mi, J.; Clary, B. M.; White, R. R. Aptamer Applications for Targeted Cancer Therapy. Future Oncol. 2010, 6, 1117-1126.
20. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. Albumin-Based Nanoparticles as Potential Controlled Release Drug Delivery Systems. J. Controlled Release 2012, 157, 168-182.
21. Gong, G.; Xu, Y.; Zhou, Y.; Meng, Z.; Ren, G.; Zhao, Y.; Zhang, X.; Wu, J.; Hu, Y. Molecular Switch for the Assembly of Lipophilic Drug Incorporated Plasma Protein Nanoparticles and in Vivo Image. Biomacromolecules 2012, 13, 23-28.
22. Xue, Z.; Shan, X.; Lapeyre, B.; Melese, T. The Amino Terminus of Mammalian Nucleolin Specifically Recognizes Sv40 T-Antigen Type Nuclear Localization Sequences. Eur. J. Cell Biol. 1993, 62, 13-21.
23. Schiff, P. B.; Horwitz, S. B. Taxol Stabilizes Microtubules in Mouse Fibroblast Cells. Proc. Natl. Acad. Sci. U. S. A. 1980, 77, 1561-1565.
24. Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. Taxol: A Novel Investigational Antimicrotubule Agent. J. Natl. Cancer Inst. 1990, 82, 1247-1259.
25. Romberg, B.; Hennink, W. E.; Storm, G. Sheddable Coatings for Long-Circulating Nanoparticles. Pharm. Res. 2008, 25, 55-71.
26. Fang, C.; Shi, B.; Pei, Y. Y.; Hong, M. H.; Wu, J.; Chen, H. Z. In Vivo Tumor Targeting of Tumor Necrosis Factor-Alpha-Loaded Stealth Nanoparticles: Effect of Mepeg Molecular Weight and Particle Size. Eur. J. Pharm. Sci. 2006, 27, 27-36.
27. Chauhan, V. P.; Stylianopoulos, T.; Martin, J. D.; Popovic, Z.; Chen, O.; Kamoun, W. S.; Bawendi, M. G.; Fukumura, D.; Jain, R. K. Normalization of Tumour Blood Vessels Improves the Delivery of Nanomedicines in a Size-Dependent Manner. Nature Nanotechnol. 2012, 7, 383-388.
28. Liu, X.; Lei, L.; Hou, J. W.; Tang, M. F.; Guo, S. R.; Wang, Z. M.; Chen, K. M. Evaluation of Two Polymeric Blends (Eva/Pla and Eva/Peg) as Coating Film Materials for Paclitaxel-Eluting Stent Application. J. Mater. Sci. Mater. Med. 2011, 22, 327-337.
29. Janssens, S.; De Zeure, A.; Paudel, A.; Van Humbeeck, J.; Rombaut, P.; Van den Mooter, G. Influence of Preparation Methods on Solid State Supersaturation of Amorphous Solid Dispersions: A Case Study with Itraconazole and Eudragit E100. Pharm. Res. 2010, 27, 775-785.
30. Yang, J. T.; Wu, C. S.; Martinez, H. M. Calculation of Protein Conformation from Circular Dichroism. Methods Enzymol. 1986, 130, 208-269.
31. Bates, P. J.; Kahlon, J. B.; Thomas, S. D.; Trent, J. O.; Miller, D. M. Antiproliferative Activity of G-Rich Oligonucleotides Correlates with Protein Binding. J. Biol. Chem. 1999, 274, 26369-26377.
32. Shi, H.; Huang, Y.; Zhou, H.; Song, X.; Yuan, S.; Fu, Y.; Luo, Y. Nucleolin Is a Receptor That Mediates Antiangiogenic and Antitumor Activity of Endostatin. Blood 2007, 110, 2899-2906.
33. Verma, A.; Stellacci, F. Effect of Surface Properties on Nanoparticle-Cell Interactions. Small 2010, 6, 12-21.
34. Gariepy, J.; Orava, E. W.; Cicmil, N. Delivering Cargoes into Cancer Cells Using DNA Aptamers Targeting Internalized Surface Portals. Biochim. Biophys. Acta, Biomembr. 2010, 1798, 2190-2200.